AG-120 - CAS 1448346-63-1
Catalog number: 1448346-63-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C28H22ClF3N6O3
Molecular Weight:
582.97
COA:
Inquire
Targets:
Isocitrate Dehydrogenase (IDH)
Description:
AG-120 is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity.
Purity:
98%
Related CAS:
1448347-49-6 (Free base)
Appearance:
White to off-white solid powder
Synonyms:
(2S)-N-(1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide; AG-120 (racemic); AG120; AG 120; AG-120; RG-120 (racemic); RG-120, RG 120; Ivosidenib (racemic);
Solubility:
Soluble in DMSO, not in water
Storage:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
MSDS:
Inquire
Shelf Life:
2 years if stored properly
InChIKey:
WIJZXSAJMHAVGX-XADRRFQNSA-N
InChI:
1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25?/m0/s1
Canonical SMILES:
O=C([C@H](CC1)N(C2=NC=CC(C#N)=C2)C1=O)N(C(C3=CC=CC=C3Cl)C(NC4CC(F)(F)C4)=O)C5=CC(F)=CN=C5
1.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P;Vachhani P;Cortes JE Curr Treat Options Oncol. 2017 Mar;18(3):17. doi: 10.1007/s11864-017-0456-2.
Approximately 40-45% of younger and 10-20% of older adults with acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The outlook is particularly gloomy for patients with relapsed and/or refractory disease (cure rates no higher than 10%). Allogeneic hematopoietic stem cell transplantation (HSCT), the only realistic hope of cure for these patients, is an option for only a minority. In recent years, much has been learned about the genomic and epigenomic landscapes of AML, and the clonal architecture of both de novo and secondary AML has begun to be unraveled. These advances have paved the way for rational drug development as new "drugable" targets have emerged. Although no new drug has been approved for AML in over four decades, with the exception of gemtuzumab ozogamycin, which was subsequently withdrawn, there is progress on the horizon with the possible regulatory approval soon of agents such as CPX-351 and midostaurin, the Food and Drug Administration "breakthrough" designation granted to venetoclax, and promising agents such as the IDH inhibitors AG-221 and AG-120, the smoothened inhibitor glasdegib and the histone deacetylase inhibitor pracinostat. In our practice, we treat most patients with relapsed/refractory AML on clinical trials, taking into consideration their prior treatment history and response to the same.
2.The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
Chen J;Yang J;Cao P Mini Rev Med Chem. 2016;16(16):1344-1358.
Isocitrate dehydrogenase (IDH) is a metabolic enzyme that converts isocitrate to α-ketoglutarate (α-KG). Genetic gain-of-function mutations in IDH1 and IDH2 confer a neomorphic activity that allow reduction of α -KG to (R)-2- hydroxyglutarate, the accumulation of which results in the development of cancers like low grade gliomas and leukemia. After treatment with AG-221 in clinical trials, a first-in-class inhibitor of mutated IDH2, 29 patients with acute myeloid leukemia or myelodysplastic syndrome experience complete remissions and the overall response rate is 59/159 (37%). Thus, IDH mutants have become intriguing targets for cancer therapeutics. In addition to providing a brief summary of IDH mutations, this review describes known inhibitors with potential activities against IDH mutants such as AG-120, AG-221, AG-881 and AGI-6780. The evolving landscape of IDH mutant inhibitors provides us an outlook on the discovery of novel, safer, and more effective cancer treatment strategies.
3.Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.
Caino MC;Altieri DC Clin Cancer Res. 2016 Feb 1;22(3):540-5. doi: 10.1158/1078-0432.CCR-15-0460. Epub 2015 Dec 9.
Small-molecule inhibitors of the phosphoinositide 3-kinase (PI3K), Akt, and mTOR pathway currently in the clinic produce a paradoxical reactivation of the pathway they are intended to suppress. Furthermore, fresh experimental evidence with PI3K antagonists in melanoma, glioblastoma, and prostate cancer shows that mitochondrial metabolism drives an elaborate process of tumor adaptation culminating with drug resistance and metastatic competency. This is centered on reprogramming of mitochondrial functions to promote improved cell survival and to fuel the machinery of cell motility and invasion. Key players in these responses are molecular chaperones of the Hsp90 family compartmentalized in mitochondria, which suppress apoptosis via phosphorylation of the pore component, Cyclophilin D, and enable the subcellular repositioning of active mitochondria to membrane protrusions implicated in cell motility. An inhibitor of mitochondrial Hsp90s in preclinical development (gamitrinib) prevents adaptive mitochondrial reprogramming and shows potent antitumor activity in vitro and in vivo. Other therapeutic strategies to target mitochondria for cancer therapy include small-molecule inhibitors of mutant isocitrate dehydrogenase (IDH) IDH1 (AG-120) and IDH2 (AG-221), which opened new therapeutic prospects for patients with high-risk acute myelogenous leukemia (AML).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Isocitrate Dehydrogenase (IDH) Products


CAS 1429176-69-1 Mutant IDH1-IN-2

Mutant IDH1-IN-2
(CAS: 1429176-69-1)

Mutant IDH1-IN-2, aslo called as SCHEMBL14831158, is an inhibitor of mutant IDH protein. It is developed for the treatment of diseases associated with such muta...

CAS 1355326-21-4 Mutant IDH1-IN-1

Mutant IDH1-IN-1
(CAS: 1355326-21-4)

Mutant IDH1-IN-1, a mutant IDH1 R132H inhibitor, could be used in some biological studies.

CAS 1448347-49-6 Ivosidenib

Ivosidenib
(CAS: 1448347-49-6)

Ivosidenib is an oral inhibitor that specifically inhibits a mutated form of IDH1 in the cytoplasm, which blocks the proliferation of tumor cells expressing IDH...

CAS 1446502-11-9 Enasidenib

Enasidenib
(CAS: 1446502-11-9)

Enasidenib, aslo known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2).

CAS 1650550-25-6 Enasidenib mesylate

Enasidenib mesylate
(CAS: 1650550-25-6)

Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes indicated for the treatment of adult patients ...

CAS 50405-58-8 TC-E 5008

TC-E 5008
(CAS: 50405-58-8)

TC-E 5008 is a selective and cancer-associated mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor (Ki = 120-190 nM), displaying >60-fold selectivity for mIDH1 ...

CAS 1432660-47-3 AGI-6780

AGI-6780
(CAS: 1432660-47-3)

AGI-6780 is an IDH2 inhibitor that potently and selectively inhibits the tumor-associated mutant IDH2/R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent agai...

CAS 6147-11-1 alpha-Mangostin

alpha-Mangostin
(CAS: 6147-11-1)

Alpha-mangostin, a prenylated xanthone derivative from Mangosteen, Garcinia mangostana L. (Clusiaceae), has shown to possess diverse pharmacological activities ...

CAS 1816331-66-4 GSK864

GSK864
(CAS: 1816331-66-4)

GSK864 is a cell penetrant, selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant with IC50 values of 8.8, 15.2 and 16.6 nM for IDH1 mutant...

CAS 1816331-63-1 GSK321

GSK321
(CAS: 1816331-63-1)

GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50= 4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 st...

AG-120
(CAS: 1448346-63-1)

AG-120 is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity.

CAS 1355326-35-0 AGI-5198

AGI-5198
(CAS: 1355326-35-0)

AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.

CAS 1429180-08-4 SCHEMBL14831541

SCHEMBL14831541
(CAS: 1429180-08-4)

SCHEMBL14831541, also called as Mutant IDH1 inhibitor, is an inhibitor of mutant IDH1 which is key enzymes found in cellular metabolism.

Quick Inquiry

Verification code

Featured Items